Back

Renin-angiotensin-aldosterone system inhibitor therapy benefit and challenges in cardio-renal patients.

27 August 2017 (12:50 - 13:05)
Organised by:
Congress Presentation Part of: Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management Heart failure, other Open Access ESC Congress 2017

About the speaker

Photo
Professor Matthew Weir

Baltimore (United States of America)

4 More presentations in this session

Presentation thumbnail
Introduction - Enabling and renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management.
Professor M. Boehm (Homburg, DE)
Slides Video
Presentation thumbnail
Changing the treatment paradigm of hyperkalaemia management to enable and optimise renin-angiotensin-aldosterone system inhibitor therapy.
Professor S. Anker (Berlin, DE)
Slides Video
Presentation thumbnail
Panel discussion - Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management.
Professor M. Boehm (Homburg, DE)
Slides Video
Presentation thumbnail
Summary and conclusion - Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management.
Professor M. Boehm (Homburg, DE)
Video

Access the full session

Session thumbnail
Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management

The Event

Event poster

ESC Congress 2017

27 August 2017 12:50 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources